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Hyperammonaemia and hyperethanolaemia are thought to be driving factors behind
skeletal muscle myopathy in liver disease, that is, cirrhosis. Despite this, the singular and
combined impacts of ethanol‐ and ammonia‐induced protein catabolism are poorly
defined. As such, we aimed to dissect out the effects of ammonia and ethanol on muscle
catabolism. Murine C2C12 myotubes were treated with ammonium acetate (10mM) and
ethanol (100mM) either alone or in combination for 4 hr and/or 24 hr. Myotube
diameter, muscle protein synthesis and anabolic and catabolic signalling pathways were
assessed. In separate experiments, cells were cotreated with selected inhibitors of
protein breakdown to assess the importance of proteolytic pathways in protein loss with
ammonia and ethanol. Ammonia and ethanol in combination resulted in a reduction in
myotube width and total protein content, which was greater than the reduction observed
with ammonia alone. Both ammonia and ethanol caused reductions in protein synthesis,
as assessed by puromycin incorporation. There was also evidence of impairments in
regulation of protein translation, and increased protein expression of markers of muscle
protein breakdown. Myotube protein loss with ammonia plus ethanol was not affected
by autophagy inhibition, but was completely prevented by proteasome inhibition. Thus,
combined ammonia and ethanol incubation of C2C12 myotubes exacerbated myotube
atrophy and dysregulation of anabolic and catabolic signalling pathways associated with
either component individually. Ubiquitin proteasome‐mediated protein breakdown
appears to play an important role in myotube protein loss with ethanol and ammonia.
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1 | INTRODUCTION
It is increasingly recognised that patients with chronic liver disease or
cirrhosis, present with a loss of skeletal muscle mass (Dasarathy &
Merli, 2016; Periyalwar & Dasarathy, 2012); this can be particularly
devastating due to the fact that during the protracted decline towards
liver failure the burden falls on other organ systems, such as skeletal
muscle, to compensate for the failing liver and maintain a degree of
homoeostasis, that is, by ammonia detoxification. It is therefore no
surprise that the presence of muscle wasting in cirrhosis patients has
been shown to be a strong predictor of mortality (Montano‐Loza et al.,
2012), and a strong determinant of survival both pre‐ and postliver
transplantation (Englesbe et al., 2010; Merli et al., 2010). Recent
evidence has suggested that impaired muscle protein metabolism in
liver disease patients is the primary cause of muscle wasting observed
in cirrhosis (Dasarathy & Merli, 2016). While the aetiology of muscle
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wasting in liver disease is multifactorial, both alcohol consumption
(and resulting hyperethanolaemia) and hyperammonaemia have
emerged as potential driving factors.
A major cause (second only to hepatitis) of liver failure is excessive
alcohol intake. Chronic alcohol abuse is well known to cause myopathy
and wasting independent of liver disease. Ethanol has been consistently
linked to direct impairments in protein metabolism (Steiner & Lang,
2015), leading to a catabolic state in skeletal muscle, and is believed to
be a major cause of muscle myopathy–atrophy (Preedy et al., 2003) and
insulin resistance (Lindtner et al., 2013). Studies using cell‐based
systems and in vivo animal models have shown that ethanol exposure
(acute and chronic) decreases rates of protein synthesis (Hong‐Brown,
Frost, & Lang, 2001; Lang, Frost, & Vary, 2007; Preedy, Keating, &
Peters, 1992). The underlying mechanisms regulating this process
remain incompletely understood, but impairment of mechanistic target
of rapamycin (mTOR) complex 1–regulated pathways, via decreased
phosphorylation of its putative downstream targets ribosomal protein
S6 kinase 1 (p70 S6K1), eukaryotic initiation factor (eIF), 4E binding
protein 1 (4E‐BP1) and ribosomal protein S6 (rpS6) is a common
observation in response to ethanol exposure (V. Kumar, Frost, & Lang,
2002; Lang et al., 2004). The effects of ethanol on muscle protein
breakdown are less well understood. One study reported that alcohol
impaired the ability of insulin‐like growth factor 1 and insulin to
suppress muscle protein breakdown, but no effect on basal rates was
observed (Hong‐Brown et al., 2001). More recent data have suggested a
role for alcohol in autophagy‐mediated cellular degradation, with
inhibition of autophagy pathways in muscle cells being shown to
prevent ethanol‐induced increases in protein breakdown (Thapaliya
et al., 2014). Other studies, however, have shown little or no change in
muscle protein breakdown with alcohol, using stable isotope methods in
vitro (Hong‐Brown et al., 2001), or 3‐methylhistidine release in human
studies (Reinus, Heymsfield, Wiskind, Casper, & Galambos, 1989). Thus,
the impact of alcohol on muscle protein turnover remains unclear.
Hyperammonaemia (an excess of systemic ammonia above the
normal range approximately >65 µM) is a major secondary conse-
quence of liver failure and has been established as a cause of toxicity
in many cell types (Holecek, 2015; Qiu et al., 2012; Wilkinson,
Smeeton, & Watt, 2010). Experimental models of hyperammonaemia
and liver disease have consistently observed reductions in muscle
mass (Bosoi et al., 2016; Qiu et al., 2013), and a strong relationship
between muscle wasting and hyperammonaemia in cirrhosis patients
has been reported (Qiu et al., 2013). Moreover, a recent study
demonstrated that ammonia lowering therapy in hyperammonaemic
portacaval anastomosis (PCA) rats resulted in improvements in muscle
phenotype and protein metabolism (A. Kumar et al., 2017). The
mechanisms for hyperammonaemia‐related myopathy and wasting
remain unclear, but it has been proposed that alterations in fuel
metabolism (required for efficient ammonia detoxification) may limit
energy supply required for adenosine triphosphate (ATP)‐consuming
protein synthesis (Davuluri, Allawy, et al., 2016; Davuluri, Krokowski,
et al., 2016). Excess ammonia has also been demonstrated to
upregulate myostatin, a negative regulator of muscle mass, which
may impair messenger RNA (mRNA) translation leading to a
suppression of muscle protein synthesis (Qiu et al., 2013). Further,
hyperammonaemia has also been proposed to increase muscle protein
breakdown, putatively through the activation of autophagy, thereby
contributing to muscle mass loss with cirrhosis (Qiu et al., 2012).
On top of the vagaries surrounding the roles of hyperethanolaemia
and hyperammonaemia individually, there is the potential that the
combination of elevated ammonia and alcohol would exacerbate the
impairment in muscle protein metabolism more than each component
individually, potentially increasing the severity of the associated
hepatic myopathy. This is a proposition supported by the observation
that alcoholic liver disease patients show a greater degree of muscle
wasting than liver disease associated with other causes (Sobhonslid-
suk, Nantiruj, & Songchitsomboon, 2001; Song et al., 2016). None-
theless, mechanistic understanding into the combined effects of the
these established and direct drivers of liver disease–induced muscle
wasting is lacking, and the individual and potential synergistic
interactions of combined ethanol and ammonia on muscle protein
turnover have not previously been investigated. Thus, the aim of the
current study was to define the effects of ethanol and ammonia on
anabolic and catabolic signalling pathways, exploring any potential
interactions between ammonia and ethanol related to the dysregula-
tion of skeletal muscle protein metabolism. We used an in vitro model
of hyperammonaemia, exposing C2C12 myotubes to 10mM ammo-
nium (creating intracellular levels observed in muscle in cirrhosis; Qiu
et al., 2013), combined with ethanol exposure at doses previously
shown to impair protein metabolism in muscle cells (Hong‐Brown,
Brown, Huber, & Lang, 2006). We also aimed to determine the role of
muscle protein breakdown in protein loss with ethanol and ammonia
exposure, by using chemical inhibitors of proteolytic pathways to
assess the mechanism of protein catabolism.
2 | MATERIALS AND METHODS
2.1 | Cell culture
Murine C2C12 myoblasts (European Collection of Authenticated Cell
Cultures, Salisbury, UK) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Thermo Fisher Scientific Waltham, MA) containing 10%
(vol/vol) foetal bovine serum, 1% (vol/vol) antibiotic–antimycotic solution
and 4mM L‐glutamine (all from Sigma‐Aldrich, Gillingham, UK) at 37°C
and 5%CO2. Myoblasts were seeded onto six‐well multidishes (Nunclon™
Delta; Thermo Fisher Scientific) and at ~90% confluency, and differentia-
tion was initiated by changing the medium to DMEM containing 2% (vol/
vol) horse serum. The media was replaced every 48 hr. Experiments were
performed on Days 4–5 postinduction of differentiation. Cells were
treated with 10mM ammonium acetate or 100mM ethanol (either alone
or in combination). After 4 and 24hr, cells were harvested in
homogenisation buffer (50mM Tris–HCl, pH 7.5, 1mM ethylenediami-
netetraacetic acid, 1mM ethylene glycol‐bis(β‐aminoethyl ether)‐N,N,N′,
N′‐tetraacetic acid, 10mM β‐glycerophosphate, 50mM NaF and com-
plete protease inhibitor cocktail tablet (Roche, Welwyn Garden City, UK)
for immunoblotting analysis (see below). In separate experiments, cells
were also harvested after 24 hr in 0.3M NaOH for measurement of total
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protein, RNA and DNA (see below). A technical replicate number of n=
5–6 well replicates were used for each treatment group, and each
experiment was performed two times. For chemical inhibitor experi-
ments, the proteasome inhibitor MG‐132 (20 µM; Sigma‐Aldrich), or
autophagy inhibitor chloroquine (CQ; 10 µM; Sigma‐Aldrich), were added
at the onset of ammonia and ethanol treatments. Dimethyl sulfoxide at a
final concentration of 0.1% (vol/vol) was added to untreated cells as a
vehicle control (Ctl). After 24 hr, cells were harvested in 0.3M NaOH for
assessment of total protein, RNA and DNA.
2.2 | Cell imaging
Following 24 hr of ammonia and/or ethanol treatment, light micro-
scope images were taken for measurement of myotube width (which
was calculated by measuring 200 myotubes across 10–15 images per
treatment). For assessment of cell viability, cells were stained after
24 hr with trypan blue to assure cell viability was maintained. Cells
were incubated for 1–2min with 0.4% (vol/vol), washed with
phosphate‐buffered saline and visualised using a light microscope.
Viability was assessed visually (i.e., nonviable cells were stained and
viable cells were unstained).
2.3 | Protein, RNA and DNA measurements
Protein, RNA and DNA were measured using the method described
by Forsberg, Nilsson, Werneman, Bergström, and Hultman (1991).
Samples collected in 0.3M NaOH were incubated at 37°C for 20min
for extraction of alkaline‐soluble protein as a proxy for total
intracellular protein. Protein was quantified using a Nanodrop
(Thermo Fisher Scientific, Waltham, MA), before the addition of
1M PCA to the samples and incubation at 4°C for 30min. Samples
were then centrifuged, and the supernatant was quantified for RNA.
Following removal of the supernatant, 2M PCA was added to the
pellet and samples were incubated at 70°C for 1 hr. The resulting
supernatant was used for DNA quantification.
2.4 | Muscle protein synthesis measurements
Relative muscle protein synthesis was assessed during the first 4 hr of
treatment using the surface sensing of translation method (Schmidt,
Clavarino, Ceppi, & Pierre, 2009), which involves incubating the cells in
vitro with puromycin (a tyrosol‐transfer RNA analogue) and with
subsequent detection of its incorporation with immunoblotting. Puromy-
cin (at a final concentration 1 µM) was added to the cells at 0 hr along
with each treatment, and at 4 hr, cells were harvested in homogenisation
buffer for protein extraction and measurement of puromycin‐labelled
peptides using immunoblotting (see below), using a mouse monoclonal
puromycin antibody (12D10; EMD Millipore, Burlington, MA).
2.5 | Immunoblotting
Cell lysates were prepared by passing samples through gel‐loading
pipette tips and centrifugation (13,000g for 10min; 4°C). Lysates
(10 µg protein) were loaded onto Criterion XT 12% Bis‐Tris Gels
(Bio‐Rad, Watford UK) for electrophoresis at 200 V for 1 hr. Samples
were transferred to polyvinylidene fluoride membranes for 45min at
100 V; membranes were blocked in 2.5% (wt/vol) bovine serum
albumin for 1 hr at room temperature. Membranes were incubated
overnight at 4°C in the presence of the following primary antibodies:
mTOR Ser2448 (#5536), protein kinase B (AKT) Ser473 (#4060),
p70 S6K1 Thr389 (#9234), 4E‐BP1 Thr37/46 (#2855), eukaryotic
elongation factor 2 (eEF2) Thr56 (#2331), 5’ adenosine monopho-
sphate-activated protein kinase (AMPK) Thr172 (#2531), forkhead
box protein O1 (FOXO1) Ser256 (#9461), FOXO3 Ser253 (#13129),
muscle atrophy F‐box (MAFbx), muscle RING‐finger protein 1
(MuRF1; #MP3401), Unc‐51 like autophagy activating kinase 1
(ULK1) Ser555 (#5869) and light chain 3B (#2775). All antibodies
were purchased from Cell Signaling Technology (Danvers, MA)
except MAFbx (Constantin, McCullough, Mahajan, & Greenhaff,
2011) and MuRF1, the latter of which was purchased from ECM
Biosciences (Versailles, KY). Membranes were cut horizontally in the
region of the molecular weight of each target (~20–30 kDa),
according to the datasheet of the manufacturer. Membranes were
washed with tris-buffered saline (TBS)‐Tween and incubated in
horseradish peroxidase (HRP)–conjugated secondary antibody
(1:2,000 dilution; New England Biolabs, Hitchin, UK) for 1 hr at
room temperature. Membranes were further washed in TBS‐Tween,
and then, bands were detected using chemiluminescent HRP
substrate (EMD Millipore, Burlington, MA) on a Chemidoc XRS
Imaging System (Bio‐Rad). Bands were quantified from images taken
from the same exposure time for each target. Membranes were
stained with Coomassie to correct for loading anomalies.
2.6 | Statistical analyses
Data (technical well replicates) were analysed by one‐way analysis of
variance (ANOVA) using Tukey’s multiple comparison test to
evaluate differences between the four treatment groups (Ctl,
ammonia, ethanol and ammonia plus ethanol; p < 0.05 was considered
as statistically significant). In the case of data with multiple time
points, results were analysed by two‐way ANOVA with Tukey’s post
hoc test to locate specific differences. All data are presented as
mean ± standard error of the mean.
3 | RESULTS
3.1 | Cell viability following 24 hr ammonia and
ethanol treatments
Initial tests aimed to verify whether treatment of C2C12 myotubes
with ethanol or ammonia (alone or in combination) would cause
adverse effects related to cell viability. Trypan blue staining after
24 hr showed an absence of trypan blue–positive cells with either
ethanol or ammonia treatments alone or in combination (Figure 1a);
thus, the cells remained viable.
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3.2 | Myotube diameter and protein–RNA–DNA
content following 24 hr ammonia and ethanol
treatments
Ammonia incubations caused a significant decrease in myotube diameter
after 24 hr (−13 ±2%, p<0.001 vs. Ctl; Figure 1b), while a decrease in
myotube diameter was also observed with ethanol incubation (−16±2%,
p<0.001 vs. Ctl). The combination of ammonia and ethanol incubations
resulted in a decrease in myotube width (−23±2%, p<0.001 vs. Ctl),
which was significantly lower than ammonia treatment alone (p<0.05 vs.
Ctl). In line with these observations, total protein content of the cells was
significantly reduced following 24hr ammonia (−10±1%, p<0.001 vs.
Ctl; Figure 1c) and ethanol (−10±2%, p<0.001 vs. Ctl; Figure 1c)
treatment. Ammonia and ethanol treatment in combination caused a
decrease in total protein (–19±1%, p<0.001 vs. Ctl) that was
significantly lower than the reduction with either ammonia or ethanol
alone (p<0.01 vs. ammonia; p<0.01 vs. ethanol; Figure 1c). Total RNA
was decreased with ammonia (−21±2%, p<0.001 vs. Ctl), ethanol
(−12±1%, p<0.001 vs. Ctl) and ammonia plus ethanol (−27±1%,
p<0.001 vs. Ctl) treatment (Figure 1d). Total DNA content was also
reduced following 24hr treatment with ammonia (−18±2%, p<0.001 vs.
Ctl), ethanol (−10±2%, p<0.05 vs. Ctl) and ammonia plus ethanol
(−19±2%, p<0.001 vs. Ctl; Figure 1e).
3.3 | Muscle protein synthesis and
anabolic–catabolic signalling following ammonia
and ethanol treatment
Protein synthesis was assessed by the quantification of puromycin
incorporation over a 4‐hr duration (prior to signal saturation). Both
ammonia and ethanol (alone and combined) significantly decreased
puromycin labelling (−15 ± 3%, p < 0.05 vs. Ctl with ammonia;
−20 ± 4%, p < 0.001 vs. Ctl with ethanol; −12 ± 3%, p < 0.05 vs. Ctl
with ammonia plus ethanol; Figure 2). Phosphorylated mTOR
(Ser2448; 289 kDa) was significantly reduced following 4 hr ammonia
(−24 ± 4%, p < 0.01 vs. Ctl; Figure 3a), ethanol (−44 ± 4%, p < 0.001 vs.
Ctl) and ammonia plus ethanol (−52 ± 3%, p < 0.001 vs. Ctl) treatments.
By 24 hr, there were no changes in phosphorylated mTOR with each
treatment compared to Ctl. Ammonia and ethanol treatments also
caused a decrease in phosphorylated AKT (Ser473; 60 kDa; −25 ± 8%,
p < 0.05 vs. Ctl with ammonia; −49 ± 3%, p < 0.001 vs. Ctl with ethanol;
Figure 3b), and this reduction was also observed with ammonia plus
ethanol treatment (−54 ± 3%, p < 0.001 vs. Ctl). After 24 hr, AKT
Ser473 phosphorylation was not different from Ctls with either
ammonia or ethanol treatment, but was significantly reduced with
ammonia plus ethanol (Figure 3b). Phosphorylation of p70 S6K1
(Thr389; 60–70 kDa) was similarly reduced with all treatments after 4
hr (26 ± 4%, p < 0.01 vs. Ctl with ammonia; −36 ± 5%, p < 0.001 vs. Ctl
with ethanol; −38 ± 2%, p < 0.001 vs. Ctl with ammonia + ethanol;
Figure 3c). At 24 hr, p70 S6K1 phosphorylation was unaffected by
ethanol treatment, but was reduced by both ammonia (−27 ± 3%, p <
0.01 vs. Ctl) and ammonia plus ethanol (−59 ± 3%, p < 0.001 vs. Ctl)
treatments. Expression of 4E‐BP1 Thr37/46 (15–20 kDa) was also
significantly decreased by ethanol incubations (−35 ± 4%, p < 0.01 vs.
Ctl) and ammonia (−27 ± 6%, p < 0.001 vs. Ctl) treatment alone, or
combined (−47 ± 4%, p < 0.001 vs. Ctl; Figure 3d). 4E‐BP1 phosphor-
ylation was not different from Ctl with any of the treatments at 24 hr
(Figure 3d). At both time points measured, treatment with ammonia
alone (+934 ± 43%, p < 0.001 vs. Ctl at 4 hr; +688 ± 17%, p < 0.001 vs.
Ctl at 24 hr), or with ethanol (+851 ± 58%, p < 0.001 vs. Ctl at 4 hr;
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F IGURE 1 Changes in cell viability, myotube diameter and total protein, RNA and DNA in C2C12 myotubes following treatment with
ammonia (10mM), ethanol (100mM) or ammonia plus ethanol combination. C2C12 myotubes were treated for 24 hr with ammonia or ethanol
(alone or in combination), before being stained with trypan blue (a). Images were used to calculate myotube diameter (b). In separate
experiments, total protein (c), RNA (d) and DNA (e) were extracted and quantified. Data are expressed as mean ± standard error of the mean
(n = 6 replicates per treatment). ap < 0.05 versus Ctl. bp < 0.05 versus ammonia. cp < 0.05 versus ethanol. Amm, ammonia; Ctl, control;
EtOH, ethanol [Color figure can be viewed at wileyonlinelibrary.com]
+723 ± 14%, p < 0.001 vs. Ctl at 24 hr), caused an increase in
phosphorylated eEF2 Thr56 (95 kDa), but ethanol alone had no effect
on eEF2 phosphorylation (Figure 3e). Phosphorylation of AMPK at
Thr172 (62 kDa) was not significantly altered by any of the treatments
at 4 hr (Figure 3f), but at 24 hr, phosphorylated AMPK was lower with
ammonia (−45 ± 4%, p < 0.05 vs. Ctl) and ammonia plus ethanol (−63 ±
2%, p < 0.05 vs. Ctl) treatment.
Ammonia and ethanol treatment alone or combined had no effect on
FOXO1 Ser256 (82 kDa) phosphorylation (Figure 4a), but FOXO3a
Ser253 (97 kDa) phosphorylation was reduced by each treatment
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F IGURE 2 Changes in protein synthesis measured by puromycin labelling in C2C12 myotubes following treatment with ammonia, ethanol or
ammonia and ethanol combined. C2C12 myotubes were treated for 4 hr with ammonia or ethanol (alone or in combination) in the presence of
puromycin. Cell lysates were analysed for puromycin labelling by immunoblotting to assess protein synthesis (a, b). Data are expressed as
mean ± standard error of the mean (n = 6 replicates per group). ap < 0.05 versus Ctl. Amm, ammonia; Ctl, control; EtOH, ethanol
F IGURE 3 Changes in phosphorylation of selected signalling targets in C2C12 myotubes following treatment with ammonia, ethanol or
ammonia and ethanol combined. C2C12 myotubes were treated for 4 or 24 hr with ammonia or ethanol (alone or in combination) before being
analysed by immunoblotting. Relative changes in phosphorylated mTOR (Ser2448; 289 kDa; a), AKT (Ser473; 60 kDa; b), p70 S6K1 (Thr389;
60–70 kDa; c), 4E‐BP1 (Thr37/46; 15–20 kDa; d), eEF2 (Thr56; 95 kDa; e) and AMPK (Thr172; 62 kDa; f). Representative blot images for targets
measured are shown in g. Data are expressed as mean ± standard error of the mean (n = 5–6 replicates per group). Blot images were obtained
from different parts of the same gel and from the same exposure time for each target. ap < 0.05 versus Ctl. bp < 0.05 versus ammonia. AKT,
protein kinase B; Amm, ammonia; Ctl, control; eEF2, eukaryotic elongation factor 2; EtOH, ethanol; mTOR, mechanistic target of rapamycin;
RAU, relative arbitrary units; 4E‐BP1, 4E binding protein 1
(−22±3%, p<0.01 vs. Ctl with ammonia; −24±5%, p <0.01 vs. Ctl with
ethanol; −19±4%, p <0.05 vs. Ctl with ammonia + ethanol; Figure 4b) at
4 hr. By 24 hr, there were no changes in FOXO3a phosphorylation.
Expression of total MAFbx (50 kDa; Figure 4c) was unaffected by each
treatment at 4 hr, but after 24 hr there were increases in MAFbx protein
with ammonia (+197 ± 29%, p <0.001 vs. Ctl), ethanol (+111 ± 45%,
p<0.05 vs. Ctl) alone and combined (+226 ± 47%, p<0.001 vs. Ctl).
MuRF1 (38 kDa; Figure 4d) total protein was no different from Ctls
following 4‐hr ethanol or ammonia treatment, but at 24 hr there were
increases in total MuRF1 with ammonia (+55 ± 14%, p<0.05 vs. Ctl) and
ammonia plus ethanol (+75 ± 7%, p<0.001 vs. Ctl) treatment. Levels of
phosphorylated ULK1 (Ser555; 140–150 kDa; Figure 4e) were not
affected by either ammonia or ethanol treatment at each time point
measured. The ratio of LC3‐II–I (14 and 16 kDa) was not affected by
ethanol at either time point but was increased following ammonia (+140
± 10%, p<0.05 vs. Ctl at 4 hr; +340 ± 49%, p<0.001 vs. Ctl at 24 hr) and
ammonia plus ethanol treatment (+168± 26%, p<0.01 vs. Ctl at 4 hr;
+267 ± 7%, p<0.001 vs. Ctl at 24 hr; Figure 4f).
3.4 | Total protein–RNA–DNA following ammonia
and ethanol treatments and inhibitors of muscle
protein breakdown
To assess the mechanistic contribution of muscle protein breakdown
pathways to the loss of cellular protein with ammonia and ethanol
treatments, selected inhibitors of key proteolytic pathways were added
to C2C12 myotubes at the point of ammonia and/or ethanol treatment.
The reduction in total cellular protein, RNA and DNA with either
ammonia, ethanol or ammonia plus ethanol treatment was not
prevented by coincubation with CQ (Figure 5a–c), although with
ammonia alone plus CQ and ethanol alone, there was no significant
difference in cellular DNA content compared to Ctl (Figure 5c). There
were no changes in the protein–DNA (Figure 5d), RNA–DNA
(Figure 5e) or RNA–protein (Figure 5f) ratios with any treatment.
However, treatment with the proteasome inhibitor MG‐132 comple-
tely prevented the loss of total cellular protein and RNA with ammonia,
ethanol and ammonia + ethanol treatment (p < 0.001 vs. A + E
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F IGURE 4 Changes in phosphorylation or protein expression of selected signalling targets in C2C12 myotubes following treatment with
ammonia, ethanol or ammonia and ethanol combined. C2C12 myotubes were treated for 4 or 24 hr with ammonia or ethanol (alone or in
combination) before being analysed by immunoblotting. Relative changes in phosphorylated FOXO1 (Ser256; 82 kDa; a), phosphorylated
FOXO3 (Ser253; 97 kDa; b), MAFbx (50 kDa; c), MuRF1 (38 kDa; d), phosphorylated ULK1 (Ser555; 140–150 kDa; e) and LC3‐II–I ratio (upper
band = LC3‐I; lower band = LC3‐II; 14 and 16 kDa; f). Representative images are shown in g. Representative blot images for targets measured
are shown in g. Data are expressed as mean ± standard error of the mean (n = 5–6 replicates per group). Blot images were obtained from
different parts of the same gel and from the same exposure time for each target. ap < 0.05 versus Ctl. Amm, ammonia; Ctl, control; EtOH,
ethanol; FOXO1, forkhead box protein O1; LC3, light chain 3; MAFbx; MuRF1, muscle RING‐finger protein 1; RAU, relative arbitrary
units; ULK1
for protein, RNA and DNA; Figure 6a–c). In these experiments,
there were no differences observed in total DNA with ammonia
treatment, or ethanol with MG‐132 compared to Ctl, but the
decrease in DNA with ammonia + ethanol was prevented by MG‐132
coincubation. There were no differences in the protein–DNA
(Figure 6d), RNA–DNA (Figure 6e) or RNA–protein (Figure 6f) ratios
in these experiments, apart from an increase in the protein–DNA
ratio with ethanol plus MG‐132 versus ethanol alone (p < 0.001 vs.
ethanol; Figure 6d).
4 | DISCUSSION
Alcohol abuse results in hyperethanolaemia, hyperammonaemia and
pathological changes in many tissues including skeletal muscle (Hong‐
Brown et al., 2001; Preedy et al., 1992; Steiner & Lang, 2015). The
presence of muscle wasting in cirrhosis patients is a strong predictor
of mortality (Montano‐Loza et al., 2012), and hyperammonaemia and
hyperethanolaemia have been consistently demonstrated to nega-
tively impact muscle protein metabolism (A. Kumar et al., 2017; Qiu
et al., 2013, 2012). Although evidence exists that individually
ammonia and ethanol impair muscle protein metabolism both in
vitro and in vivo (Hong‐Brown et al., 2006, 2001; A. Kumar et al.,
2017; Qiu et al., 2012), through incompletely defined mechanisms,
mechanistic insight into the combined effects of these direct drivers
of liver‐induced muscle wasting has not previously been investigated.
Thus, the aim of the current study was to explore both individual and
synergistic interactions between ammonia and ethanol in relation to
the mechanistic regulation of skeletal muscle catabolism in vitro. To
ensure that neither ethanol nor ammonia (alone or combined) caused
major cytotoxic effects on cell viability, trypan blue staining was
undertaken, where the absence of staining indicated that their
individual and combined atrophic effects were unrelated to wide-
spread cytotoxicity. Thus, muscle atrophy responses to both ethanol
and ammonia were unlikely related to major cytotoxicity.
In this study, as expected, muscle atrophy occurred in response to
both ethanol and ammonia exposure. Moreover, the loss of cellular
protein was exacerbated by the combined incubation with these two
factors, in line with our hypothesis that these two key perturbations
in alcoholic liver disease development might underlie this phenom-
enon. To define potential mechanisms for these observations, we
sought to substantiate previous reports surrounding the catabolic
effects of ethanol exposure on skeletal muscle protein. Previous
reports have indicated that hyperethanolaemia causes a suppression
in protein synthesis (V. Kumar et al., 2002; Lang et al., 2004), whereas
its effects on muscle protein breakdown are less well understood
(Hong‐Brown et al., 2001; Reinus et al., 1989; Thapaliya et al., 2014),
while hyperammonaemia stimulates a suppression of muscle protein
synthesis and activation of muscle protein breakdown (Dasarathy
et al., 2007; A. Kumar et al., 2017; Qiu et al., 2012). In the current
study, both ammonia and ethanol treatment resulted in robust
decreases in protein synthesis, as measured by puromycin labelling
over 4 hr, although there was no further decline in puromycin
labelling when treatments were combined. This was somewhat in
contrast to the muscle protein–mass data, where muscle loss was
exacerbated by combined treatment. This suggests that other
processes, such as protein breakdown, may be at play.
Further underlining the decrease in muscle protein synthesis
with these treatments, our quantification of anabolic signalling
proteins demonstrated early downregulation of mTOR components
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F IGURE 5 Changes in total protein, RNA and DNA in C2C12 myotubes following treatment with ammonia (10mM), ethanol (100mM)
and chloroquine (CQ). C2C12 myotubes were treated for 24 hr with ammonia and/or ethanol along with CQ (a–c) after which total protein,
RNA and DNA was extracted and quantified. From these values the protein–DNA (d), RNA–DNA (e) and RNA–protein (f) ratios were
calculated. Data are expressed as mean ± standard error of the mean (n = 6 replicates per treatment). ap < 0.05 versus Ctl. Amm, ammonia;
Ctl, control; EtOH, ethanol
(phosphorylated mTOR, AKT, p70 S6K1 and 4E‐BP1) with both
ethanol and ammonia, and furthermore, there was a greater decrease
in mTOR, AKT and 4E‐BP1 following ammonia and ethanol treatment
combined than ammonia alone. It should be noted that corresponding
total protein levels for mTOR signalling proteins were not measured
in the current study; thus, changes in phosphorylation could feasibly
have been due to altered protein abundance. Nevertheless, changes
in phosphorylation for the targets measured are considered
indicative of total activity. Intriguingly, there were also distinct
differences between ethanol and ammonia in terms of their impact
on anabolic signalling. For example, by 24 hr, p70 S6K1 phosphoryla-
tion remained decreased with ammonia treatment, whereas it was no
different to Ctl in ethanol‐treated cells (all anabolic proteins
measured had returned to Ctl levels by 24 hr with ethanol). In
addition, only ammonia caused a marked upregulation of the key
translation elongation factor eEF2 (Wilson et al., 2011), suggesting
that while ethanol primarily caused impairments in translation
initiation, ammonia impacted both translation initiation and elonga-
tion processes. These findings indicate that distinct upstream
regulatory factors may have been responsible for the impairment
in protein translation with both ethanol and hyperammonaemia.
It has been previously reported that eef2 kinase, the primary kinase
responsible for phosphorylation (and thereby inhibition) of eEF2, is
regulated by a variety of conditions including endoplasmic reticulum (ER)
stress (Boyce et al., 2008), cytoplasmic pH changes (Dorovkov, Pavur,
Petrov, & Ryazanov, 2002), amino acid availability (Wang, Campbell,
Miller, & Proud, 1998) and Ca2+–calmodulin (Ryazanov, 1987). Thus, it is
feasible that changes in one or more of the above factors were
responsible for the downstream effects on eEF2 with hyperammonaemia,
but not hyperethanolaemia. However, it should be noted that a previous
study reported marked upregulation of eEF2 phosphorylation in C2C12
cells with ethanol administration (Hong‐Brown, Brown, Huber, & Lang,
2007). It is not clear why such differences were observed in our study,
but could reflect differences in experimental protocol (e.g., duration of
ethanol treatment, use of myotubes vs. myoblasts). It was also shown in
the same study that ethanol‐mediated eEF2 phosphorylation was AMPK‐
dependent (Hong‐Brown et al., 2007), while in the current study we
found no effect of ethanol on AMPK activation status. Furthermore,
previous work with C2C12 cells reported that ammonia also resulted in
increased AMPK phosphorylation (Hong‐Brown et al., 2007), whereas in
the current study there was a decline after 24 hr. Again, the reason for
these differences are not clear, and more work is required to fully define
the mechanisms that underlie ammonia‐induced impairments in mRNA
translation. It was recently identified that activation of eIF2α may
represent a major mechanism by which ammonia impairs muscle protein
synthesis (Davuluri, Krokowski, et al., 2016), via decreased assembly of
43S initiation complexes. However, under the present conditions, we
found there was no effect of either ethanol or ammonia on
phosphorylation (ser51) of eIF2α (data not shown).
To determine the importance of muscle protein breakdown on
myotube protein loss with ethanol and ammonia, cells were treated
with inhibitors of major proteolytic pathways (i.e., ubiquitin protea-
some pathway and autophagy). Hyperammonaemia has previously
been linked to increased autophagy flux, which was proposed to
contribute to muscle loss with cirrhosis (Qiu et al., 2012), while
ethanol has also been reported to activate autophagy in muscle
(Thapaliya et al., 2014). In this study, inhibition of autophagy using
CQ did not prevent the loss of total protein, RNA or DNA, either in
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F IGURE 6 Changes in total protein, RNA and DNA in C2C12 myotubes following treatment with ammonia (10mM), ethanol (100mM) and
MG‐132. C2C12 myotubes were treated for 24 hr with ammonia and/or ethanol along with MG‐132 (a–c) after which total protein, RNA
and DNA was extracted and quantified. From these values, the protein–DNA (d), RNA–DNA (e) and RNA–protein (f) ratios were calculated.
Data are expressed as mean ± standard error of the mean (n = 6 replicates per treatment). ap < 0.05 versus Ctl. bp < 0.05 versus ammonia.
cp < 0.05 versus ethanol. dp < 0.05 versus ammonia plus ethanol. Amm, ammonia; Ctl, control; EtOH, ethanol
the presence of ammonia or ethanol alone, or combined. While there
was evidence of autophagy activation with ammonia, which resulted
in increases in the ratio of LC3‐II to LC3‐I (a commonly used marker
of autophagy; Karim et al., 2007), these findings suggest that
activation of autophagy may not be a driving factor in the global
changes to protein metabolism under these conditions. There was
also no evidence of activation of autophagy with ethanol treatment
alone, in contrast with some previous studies (Thapaliya et al., 2014),
where alcoholic cirrhotic patients and ethanol‐fed mice were
reported to have increased markers of autophagy, including elevated
LC3‐II protein. These contrasting observations between studies could
feasibly be due to differences in dose–duration of ethanol adminis-
tration, species studied, or use of an in vitro versus in vivo model.
Nevertheless, under the present conditions, there was no evidence to
suggest that activation of autophagy pathways underlied the
catabolic changes in muscle with hyperethanolaemia.
In contrast with autophagy inhibition, suppression of proteaso-
mal‐mediated protein degradation prevented the loss of myotube
protein, both with ammonia and ethanol alone and in combination.
Furthermore, the losses in RNA and DNA with ammonia plus ethanol
were also prevented by proteasome inhibition, indicating that
maintenance of proteostasis also protected against cell loss. Protein
expression of MAFbx, a regulator of ubiquitin proteasome‐mediated
breakdown (Bodine & Baehr, 2014), was increased after 24 hr with
both ammonia and ethanol, consistent with both these factors
causing activation of ubiquitin proteasome pathway–mediated
protein breakdown. MuRF1 protein, another marker of muscle
atrophy (Bodine & Baehr, 2014), was also upregulated by ammonia
after 24 hr, but not ethanol alone, highlighting a further difference
between ammonia and ethanol in relation to their impact on
activation of proteolytic pathways. As discussed above, activation
of muscle protein breakdown has previously been described with
hyperammonaemia (A. Kumar et al., 2017; Qiu et al., 2012), although
it was reported to mainly involve autophagy activation (Qiu et al.,
2012), while changes in ubiquitin proteasome pathway components
are less clear. In the PCA rat, one study observed no changes in
mRNA expression of key ubiquitin proteasome pathway genes after
4 weeks (Dasarathy, Dodig, Muc, Kalhan, & McCullough, 2004), while
a separate study reported increases in MAFbx and proteasome
subunit mRNA expression 1–2 weeks after PCA (Dasarathy et al.,
2007). In cirrhosis patients, 20S proteasome activity and MAFbx and
MuRF1 mRNA were demonstrated to be no different from Ctls (Qiu
et al., 2012). The role of the ubiquitin proteasome pathway in
ethanol‐mediated muscle atrophy is similarly poorly understood, with
previous studies reporting no activation of ubiquitin proteasome‐
mediated proteolysis with alcohol (Thapaliya et al., 2014), while it
was also demonstrated that upregulation of MAFbx and MuRF1 with
acute alcohol exposure was not accompanied by activation of
proteolysis (Vary, Frost, & Lang, 2008). Clearly, more work is
necessary to determine the precise role that ubiquitin proteasome‐
mediated breakdown plays in myopathy associated with both alcohol
and hyperammonaemia.
In summary, the findings from this study indicate that the
combination of ammonia and ethanol exerted a greater impact on
dysregulation of protein metabolism than either factor alone.
Both factors caused impairments in regulation of protein transla-
tion as well as activation of proteolytic pathways, but through
common and distinct mechanisms. Ubiquitin proteasome‐
mediated protein breakdown appears to be an important factor
contributing to the catabolic state with both ethanol and
hyperammonaemia. These findings provide greater insight into
the interactions between hyperammonaemia and hyperethano-
laemia in relation to their regulation of muscle catabolism in vitro
and provide novel mechanistic understanding into the combined
effects of the two most established and direct drivers of liver
disease–induced muscle wasting. While there are limitations
associated the use of immortalised cell lines such as C2C12 cells,
we performed the current study in vitro due to the fact that in
vivo studies can introduce indirect confounding variables not
reflecting ammonia–ethanol effects on muscle. This enabled us to
use a muscle‐specific approach to gain important insight into the
interactions between hyperammonaemia and hyperethanolaemia
in relation to the regulation of skeletal muscle catabolism in vitro.
Moreover, previous studies have also shown good agreement with
the effects of ammonia in vivo and in C2C12 myotubes
(Davuluri, Allawy et al., 2016; A. Kumar et al., 2017). Never-
theless, future work must focus on determining whether this
interaction exists in vivo, and whether strategies aimed at
lowering hyperammonaemia and/or ethanol can reverse the
catabolic changes in skeletal muscle.
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